(Press-News.org) Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology’s annual meeting.
At this year’s scientific forum, Dr. Dennis Slamon, chair of hematology-oncology and director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center, will present findings from the NATALEE clinical trial (abstract LBA500), which looks at adding ribociclib, a targeted therapy drug, to standard hormone therapy as adjuvant treatment for patients with early hormone-receptor positive/HER2 negative breast cancer. The results will be highlighted during the oral presentation on June 2 at 2:45pm CT in Hall D1.
Dr. Timothy Cloughesy, professor of neuro-oncology at the David Geffen School of Medicine at UCLA, is the senior author of abstract LBA1, which highlights INDIGO clinical trial results, a global, randomized double-blinded, phase 3 study of vorasidenib verse placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. The findings will be presented during the plenary session on June 4 at 1PM CT in Hall B1.
"In this time of remarkable and rapid advancement in cancer medicine, the data and experiences presented during these sessions at ASCO offer important insights into emerging areas of study, and allow a critical open forum for participation with a wide range of top experts,” said Dr. Michael Teitell, director of the UCLA Jonsson Comprehensive Cancer Center.
Highlights of noteworthy presentations at ASCO 2023 that feature contributions from UCLA researchers include (all times are listed in CDT):
BREAST CANCER
Oral Abstract Session
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
Abstract: LBA500
Presenter: Dennis Slamon, MD, PhD
Date: June 2 at 2:45PM
Location: Hall D1
Poster Session
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
Abstract: TPS1118 | Poster Bd #: 335b
Presenter: Sara A. Hurvitz, MD, FACP
Date: June 4 from 8 to 11AM.
Location: Hall A
Poster Session
UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.
Abstract: TPS1116 | Poster Bd #: 334b
Presenter: Nicholas Patrick McAndrew, MD, MSCE
Date: June 4 from 8 to 11AM.
Location: Hall A
Poster Session
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
Abstract: TPS1114 | Poster Bd #: 333b
Presenter: Sara A. Hurvitz MD, FACP
Date: June 4 from 8 to 11AM.
Location: Hall A
BRAIN TUMORS
Plenary Session
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Abstract: LBA1
Senior Author: Timothy Cloughesy, MD
Date: June 4 at 1PM
Location: Hall B1.
Poster Session
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.
Abstract: 2063 | Poster Bd #: 420
Presenter: Benjamin M. Ellingson, PhD
Date: June 3 from 1:15 to 4:15PM
Location: Hall A
PROSTATE CANCER
Poster Session
Early findings from the GARUDA trial: The impact of a genetic signature of late radiation toxicity on prostate cancer treatment decision making.
Abstract: 5089 | Poster Bd #: 183
Presenter: Joanne B. Weidhaas, MD, PhD
Date: June 3 from 8 to 11AM
Location: Hall A
Poster Discussion Session
PSMA PET guided salvage radiotherapy among patients with prostate cancer in the post-prostatectomy setting: A single center post-hoc analysis.
Abstract: 5009 | Poster Bd #: 103
Presenter: Jeremie Calais, MD, MSc
Date: June 3 from 1:15 to 2:45PM
Location: E450
Poster Session
PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.
Abstract: 5091 | Poster Bd #: 185
Presenter: Wesley Robert Armstrong, BS
Date: June 3 from 8 to 11AM
Location: Hall A
Poster Session
Genomic alterations and self-reported Agent Orange exposure in United States veterans with metastatic prostate cancer.
Abstract: 5068 | Poster Bd #: 162
Presenter: JJ Haijing Zhang, MD
Date: June 3 from 8 to 11AM
Location: Hall A
Poster Discussion Session
Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers.
Abstract: 5011 | Poster Bd #: 105
Presenter: Wolfgang Peter Fendler, MD
Date: June 3 from 1:15 to 2:45PM
Location: E40
BLOOD CANCERS
Poster Session
UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.
Abstract: 7024 | Poster Bd #: 154
Presenter: Sunmin Park, MD, PhD
Date: June 5 from 8 to 11AM
Location: Hall A
COLORECTAL CANCER
Poster Session
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.
Abstract: TPS3630 | Poster Bd #: 327a
Presenter: J. Randolph Hecht, MD
Date: June 5 from 8 to 11AM
Location: Hall A
KIDNEY CANCER
Poster Session
Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.
Abstract: 4554 | Poster Bd #: 46
Presenter: Brian M. Shuch, MD
Date: June 3 from 8 to 11AM
Location: Hall A
OVARIAN CANCER
Poster Session
Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
Abstract: 3082 | Poster Bd #: 280
Presenter: Gottfried E. Konecny, MD
Date: June 3 from 8 to 11AM
Location: Hall A
END
ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and more
UCLA investigators present the latest cancer research at the American Society of Clinical Oncology annual meeting June 2 to June 6 in Chicago
2023-05-22
ELSE PRESS RELEASES FROM THIS DATE:
Cancer researchers join forces against deadliest brain tumors in children
2023-05-22
Virginia Tech researchers with the Fralin Biomedical Research Institute at VTC have joined a Children’s National Hospital effort to treat deadly brain tumors with ultrahigh frequency sound waves.
The scientists are studying how to use an emerging technology called focused ultrasound to fight diffuse midline glioma (DMG), one of the most lethal childhood brain cancers with a nearly 100 percent rate of mortality within five years of diagnosis.
A multi-institutional team led by Javad Nazarian, a principal investigator with Children’s National Hospital, will study how to use focused ultrasound to create ...
Eruption of Tonga underwater volcano found to disrupt satellite signals halfway around the world
2023-05-22
An international team has used satellite- and ground-based ionospheric observations to demonstrate that an air pressure wave triggered by volcanic eruptions could produce an equatorial plasma bubble (EPB) in the ionosphere, severely disrupting satellite-based communications. Their findings were published in the journal Scientific Reports.
The ionosphere is the region of the Earth's upper atmosphere where molecules and atoms are ionized by solar radiation, creating positively charged ions. The area with the highest concentration of ionized particles is called the F-region, an area 150 to 800 km above the Earth's surface. The F-region plays ...
Adverse pregnancy outcomes increase stroke risk
2023-05-22
Investigators from the Smidt Heart Institute at Cedars-Sinai found that women who experience an adverse pregnancy outcome—such as gestational hypertension, preeclampsia or preterm birth—have a higher risk of developing stroke in their lifetime, and at a younger age.
The findings, published today in the peer-reviewed journal Stroke, also found that compared to women with one uncomplicated pregnancy, a woman who had two or more pregnancies impacted by an adverse pregnancy outcome had a twofold higher increase of stroke.
“We understand from past studies in the U.S. that women have a greater risk of experiencing a stroke and a disproportionate ...
Earlier snowpack melt in the West could bring summer water scarcity
2023-05-22
Snow is melting earlier, and more rain is falling instead of snow in the mountain ranges of the Western U.S. and Canada, leading to a leaner snowpack that could impact agriculture, wildfire risk and municipal water supplies come summer, according to a new study from the University of Colorado Boulder.
Published in Nature Communications Earth & Environment, the study documents more than 60 years of change in snowpack water storage across Western North America. It found that from 1950 to 2013, snowpack water storage ...
What’s the relationship between cancer survivors’ tobacco use, symptom burden, and motivation to quit smoking?
2023-05-22
Study’s findings may help inform tobacco cessation support efforts.
In a recent study, current smoking and vaping were associated with a higher burden of symptoms among adult cancer survivors, but these symptoms were not related to survivors’ desire to quit smoking. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Continued smoking after a cancer diagnosis lowers survival rates, increases the likelihood of additional cancers, and decreases the effectiveness ...
Tokyo Tech, Tohoku University, Fujitsu, and RIKEN start collaboration to develop distributed training of Large Language Models
2023-05-22
Tokyo Institute of Technology (Tokyo Tech), Tohoku University, Fujitsu Limited, and RIKEN today announced that they will embark on the research and development of a distributed training of Large Language Models (LLM) [1]on supercomputer Fugaku in May 2023, within the scope of the initiatives for use of Fugaku defined by Japanese policy.
LLMs are AI models for deep learning that serve as the core of generative AI including ChatGPT[2]. The four organizations aim to improve the environment for creating LLMs that can be widely used by academia and companies, contribute to improving the research capabilities of AI in Japan, and increase the value of utilizing Fugaku in both ...
Nitrate: healthy heart or cancer risk? Meet nutrition’s Jekyll and Hyde
2023-05-22
Despite our understanding of nutrition expanding remarkably in recent times, few aspects of our diet continue to confuse and divide the experts like nitrate.
For a long time nitrate has been viewed warily, with previous research showing it could potentially be linked to causing cancer.
However, subsequent research has revealed dietary nitrate also has various cardiovascular health benefits, which could help reduce the risk of related conditions such as heart disease, dementia and diabetes.
So, how can one dietary compound have such contrasting potential risks and benefits?
Edith Cowan University’s (ECU) Nutrition and Health ...
Can charismatic robots help teams be more creative?
2023-05-22
Increasingly, social robots are being used for support in educational contexts. But does the sound of a social robot affect how well they perform, especially when dealing with teams of humans? Teamwork is a key factor in human creativity, boosting collaboration and new ideas. Danish scientists set out to understand whether robots using a voice designed to sound charismatic would be more successful as team creativity facilitators.
“We had a robot instruct teams of students in a creativity task. The robot ...
Stop eradication of small mammals to protect vital ecosystems, say scientists
2023-05-22
A new article published in the Journal of Animal Ecology suggests that current measures to protect grasslands in the Qinghai-Tibetan Plateau are damaging the ecosystem and should be stopped.
The existing policy, introduced in 2000, calls for the eradication of small burrowing mammals. These include the mountain-dwelling herbivores, the plateau pika, and another small rodent, the zokor. Both are keystone species and are known as ecosystem engineers due to their modification of and impact on the environment.
The ...
Study linking mucus plugs and COPD mortality could help save lives
2023-05-21
A retrospective analysis of patient data from the COPDGene study suggests that targeting mucus plugs could help prevent deaths from chronic obstructive pulmonary disease—the fourth leading cause of death in the United States
Many patients with chronic obstructive pulmonary disease (COPD) experience airway-clogging mucus plugs, an accumulation of mucus in the lungs that can affect quality of life and lung functioning. A new study led by researchers from Brigham and Women’s Hospital, a founding ...
LAST 30 PRESS RELEASES:
The decision to eat may come down to these three neurons
Woods Hole Oceanographic Institution researchers use the sounds of healthy coral reefs to encourage growth of a new species of coral larvae
Researchers at NYU Tandon School of Engineering and KAIST develop method to 'hear' defects in promising nanomaterial
Biodiversity increases nutrient availability
American Society of Anesthesiologists names Donald E. Arnold, M.D., FACHE, FASA, new president
Family as a wealth factor
Breathing deep: A metabolic secret of ethane-consuming archaea unraveled
NIH clinical trial will test precision medicine treatments for myeloid cancers
Novel antibody platform tackles viral mutations
myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment across US and Canada
Social determinants of health and US health care expenditures by insurer
Traumatic and adverse childhood experiences and developmental differences in psychiatric risk
Immunotherapy blocks scarring, improves heart function in mice with heart failure
Discovery finds how ovarian cancer disables immune cells
Physicists discover first “black hole triple”
A “chemical ChatGPT” for new medications
Soteria Precision Medicine Foundation partners with Translational Genomics Research Institute (TGen) to inform cancer care for Special Operations Forces
Capturing carbon from the air just got easier
Ultra-small spectrometer yields the power of a 1,000 times bigger device
Rocky planets orbiting small stars could have stable atmospheres needed to support life
A 'worrying confluence' of flood risk, social vulnerability and climate change denial
Saving the bats: Researchers find bacteria, fungi on bat wings that could help fight deadly white-nose syndrome
Project Cure CRC awards nearly $5 million in research funding
New parasite discovered amid decline of California’s unique Channel Island fox
Chemical Insights Research Institute publishes comprehensive guidance to protect community health impacted by wildland-urban interface fire events
New concussion sign identified by Mass General Brigham & Concussion Legacy Foundation scientists could identify up to 33% of undiagnosed concussions
Dehydration linked to muscle cramps in IRONMAN triathletes
Study: Marshes provide cost-effective coastal protection
New chemical treatment reduces number of plant pores that regulate water loss
Safety and security: Study shines light on factors behind refugees’ resilience
[Press-News.org] ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and moreUCLA investigators present the latest cancer research at the American Society of Clinical Oncology annual meeting June 2 to June 6 in Chicago